全文获取类型
收费全文 | 15989篇 |
免费 | 859篇 |
国内免费 | 124篇 |
专业分类
耳鼻咽喉 | 151篇 |
儿科学 | 319篇 |
妇产科学 | 351篇 |
基础医学 | 1859篇 |
口腔科学 | 393篇 |
临床医学 | 1214篇 |
内科学 | 5003篇 |
皮肤病学 | 412篇 |
神经病学 | 1281篇 |
特种医学 | 289篇 |
外科学 | 2230篇 |
综合类 | 96篇 |
一般理论 | 8篇 |
预防医学 | 1025篇 |
眼科学 | 300篇 |
药学 | 884篇 |
中国医学 | 37篇 |
肿瘤学 | 1120篇 |
出版年
2024年 | 12篇 |
2023年 | 123篇 |
2022年 | 249篇 |
2021年 | 696篇 |
2020年 | 310篇 |
2019年 | 622篇 |
2018年 | 683篇 |
2017年 | 404篇 |
2016年 | 417篇 |
2015年 | 449篇 |
2014年 | 734篇 |
2013年 | 803篇 |
2012年 | 1468篇 |
2011年 | 1475篇 |
2010年 | 767篇 |
2009年 | 687篇 |
2008年 | 1097篇 |
2007年 | 1101篇 |
2006年 | 950篇 |
2005年 | 909篇 |
2004年 | 833篇 |
2003年 | 670篇 |
2002年 | 680篇 |
2001年 | 69篇 |
2000年 | 56篇 |
1999年 | 80篇 |
1998年 | 101篇 |
1997年 | 96篇 |
1996年 | 66篇 |
1995年 | 44篇 |
1994年 | 46篇 |
1993年 | 38篇 |
1992年 | 24篇 |
1991年 | 19篇 |
1990年 | 17篇 |
1989年 | 14篇 |
1988年 | 13篇 |
1987年 | 10篇 |
1986年 | 9篇 |
1985年 | 6篇 |
1984年 | 14篇 |
1983年 | 9篇 |
1982年 | 11篇 |
1981年 | 12篇 |
1980年 | 11篇 |
1979年 | 8篇 |
1975年 | 11篇 |
1971年 | 9篇 |
1970年 | 5篇 |
1967年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
121.
Javier Sastre Eugenio Marcuello Bartomeu Masutti Matilde Navarro Silvia Gil Antonio Antón Albert Abad Enrique Aranda Joan Maurel Manuel Valladares Inmaculada Maestu Alfredo Carrato José María Vicent Eduardo Díaz-Rubio 《Journal of clinical oncology》2005,23(15):3545-3551
PURPOSE: Elderly patients constitute a subpopulation with special characteristics that differ from those of the nonelderly and have been underrepresented in clinical trials. This study was performed to determine the efficacy and safety of irinotecan (CPT-11) in combination with fluorouracil (FU) administered as a 48-hour continuous infusion twice a month in elderly patients. PATIENTS AND METHODS: Patients > or = 72 years old with metastatic colorectal cancer, Eastern Cooperative Oncology Group performance status of 0 to 1, no geriatric syndromes, and no prior treatment were treated every 2 weeks with CPT-11 180 mg/m2 plus FU 3,000 mg/m2 in a 48-hour continuous infusion. RESULTS: By intent-to-treat analysis, in 85 assessable patients, the objective response rate was 35% (95% CI, 25% to 46%), and stable disease was 33% (95% CI, 23% to 44%). Median time to progression was 8.0 months (95% CI, 6.0 to 10.0 months), and median overall survival time was 15.3 months (95% CI, 13.8 to 16.9 months). Toxicity was moderate. Grade 3 and 4 neutropenia, diarrhea, and asthenia were observed in 21%, 17%, and 13% of patients, respectively. Only one case of neutropenic fever occurred. There were two toxic deaths, one was a result of grade 4 diarrhea and acute kidney failure, and the other was a result of massive intestinal hemorrhage in the first cycle. The study of prognostic factors did not reveal any predictive factor of response. Response to treatment and baseline lactate dehydrogenase were the main factors conditioning progression-free and overall survival. CONCLUSION: Twice a month continuous-infusion CPT-11 combined with FU is a valid therapeutic alternative for elderly patients in good general condition. 相似文献
122.
Vicente Valentín Maganto Carlos Camps Herrero Joan Carulla Torrent Javier Cassinello Espinosa Javier Dorta Delgado Carlos Jara Sánchez José Andrés Moreno Nogueira 《Clinical & translational oncology》2005,7(5):205-212
INTRODUCTION: Oral trans-mucosal fentanyl citrate (OTFC) is the one drug specifically developed for the management of breakthrough pain. This study assesses the long-term safety and efficacy of OTFC standard clinical conditions. Patients and methods. Six-month observational study performed on cancer patients with episodes of breakthrough pain. Safety was assessed by recording the advent of adverse events and efficacy by the evaluating the intensity of breakthrough pain. RESULTS: 174 cancer patients were recruited into the study. All adverse reactions reported were mild or moderate. OTFC was significantly faster (time to the commencement of pain relief: 12.7 +/- 11.4 vs 32.7 +/- 18.4 minutes; p < 0.001) and potent (post-treatment pain intensity: 3.4 +/- 1.5 vs 4.3 +/- 1.5; p < 0.001) than the previously-used drugs. CONCLUSIONS: This observational study confirms the good safety profile of OTFC as well as its effectiveness over long-term period treatment of breakthrough pain. 相似文献
123.
Hironobu Shibata Masahiro Abe Kenji Hiura Javier Wilde Keiji Moriyama Toshiaki Sano Ken-Ichi Kitazoe Toshihiro Hashimoto Shuji Ozaki Shingo Wakatsuki Shinsuke Kido Daisuke Inoue Toshio Matsumoto 《Clinical cancer research》2005,11(17):6109-6115
PURPOSE: Receptor activator of nuclear factor-kappaB ligand (RANKL) is a key mediator of osteoclastogenesis. Because certain types of tumor cells aberrantly express RANKL, and because bone destruction also develops in B-cell lymphomas of bone origin, we investigated RANKL expression and the mechanisms of osteoclastogenesis in B-lymphoid neoplasms. EXPERIMENTAL DESIGN AND RESULTS: Immunohistochemistry of bone specimens resected from patients with primary B-cell lymphoma of bone with bone destruction revealed that lymphoma cells express RANKL as well as vascular endothelial cell growth factor (VEGF). The tumor cells isolated from the bone specimens enhanced osteoclastogenesis in vitro. In contrast, B-cell lymphoma infiltrating to the bone marrow without bone destruction did not express RANKL. Both RANKL and VEGF were expressed by a portion of B-lymphoid cell lines, including Daudi and IM-9. These RANKL-expressing tumor cells enhanced osteoclastogenesis from RAW264.7 cells and human monocyte-derived preosteoclasts in the absence of stromal cells/osteoblasts in a RANKL-dependent manner. Furthermore, conditioned media from Daudi cells enhanced transmigration of preosteoclasts that was inhibited by anti-VEGF antibody, suggesting that tumor cell-derived VEGF mediates recruitment of osteoclast precursors. Moreover, cocultures of B-lymphoid cell lines with osteoclasts enhanced the growth of B-lymphoid cells. CONCLUSIONS: Some malignant B cells aberrantly express functional RANKL as well as VEGF to enhance osteoclastogenesis. The coexpression of RANKL and VEGF may also contribute to the close cellular interactions with osteoclastic cells, thereby forming a vicious cycle between osteoclastic bone destruction and tumor expansion in bone. 相似文献
124.
Fernando Moreno Antón Javier Sastre Valera Belén Loboff de León Sara López-Tarruella Luis Ortega Medina Eduardo Díaz-Rubio 《Clinical & translational oncology》2005,7(7):321-323
Metastastic tumours involving the epididymis are rare and most often found in patients with disseminated disease. It is even more unusual when the metastasis of the epididymis is the first sign of tumour recurrence. We report a case of an asymptomatic recurrent colon carcinoma presenting as metastasis in the epididymis. Although metastatic cancer presenting as an intra-scrotal mass is extremely rare, it should be considered as a possibility in patients who present with a mass involving the testicle or epididymis. 相似文献
125.
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. 总被引:2,自引:0,他引:2
Emiliano Honrado Ana Osorio José Palacios Roger L Milne Lydia Sánchez Orland Díez Alicia Cazorla Kirsi Syrjakoski David Huntsman P?ivi Heikkil? Enrique Lerma Anne Kallioniemi Carmen Rivas William D Foulkes Heli Nevanlinna Javier Benítez 《Journal of clinical oncology》2005,23(30):7503-7511
PURPOSE: Morphologic and immunohistochemical studies of familial breast cancers have identified specific characteristics associated with BRCA1 mutation-associated tumors when compared with BRCA2 and non-BRCA1/2 tumors, but have not identified differences between BRCA2 and non-BRCA1/2 tumors. Because BRCA1 and BRCA2 genes participate in the DNA repair pathway, we have performed an immunohistochemical study with markers related to this pathway to establish the profile of the three groups. MATERIALS AND METHODS: We have studied two tissue microarrays that include 103 familial and 104 sporadic breast tumors, with a panel of DNA repair markers including ATM, CHEK2, RAD51, RAD50, XRCC3, and proliferating cell nuclear antigen. RESULTS: We found more frequent expression of CHEK2 in BRCA1 and BRCA2 tumors than in non-BRCA1/2 and sporadic tumors. We found absence of nuclear expression and presence of cytoplasmic expression of RAD51 in BRCA2 tumors that differentiate them from other familial tumors. We validated these results with a new series of patient cases. The final study with 253 familial patient cases (74 BRCA1, 71 BRCA2, 108 non-BRCA1/2), and 288 sporadic patient cases, has allowed us to confirm our preliminary results. Because BRCA2 tumors present a specific immunohistochemical profile for RAD51 and CHEK2 markers that is different from non-BRCA1/2 tumors, we have built a multivariate model with these markers that distinguish both tumors with an estimated probability of at least 76%. CONCLUSION: Our results suggest that BRCA2 tumors demonstrate more cytoplasmic and less nuclear RAD51 staining, and increased CHEK2 staining. This pattern may distinguish BRCA2 from familial non-BRCA1/2 tumors. 相似文献
126.
Dolores Caballero Jose A García-Marco Rodrigo Martino Victoria Mateos José M Ribera José Sarrá Angel León Guillermo Sanz Javier de la Serna Rafael Cabrera Marcos González Jorge Sierra Jesús San Miguel 《Clinical cancer research》2005,11(21):7757-7763
PURPOSE: To evaluate the efficacy of reduced intensity conditioning (RIC) allogeneic transplant in 30 patients with poor-prognosis chronic lymphocytic leukemia (CLL) and/or high-risk molecular/cytogenetic characteristics. EXPERIMENTAL DESIGN: Eighty-three percent of patients had active disease at the moment of transplant. That is, 14 of the 23 patients analyzed (60%) had unmutated immunoglobulin variable heavy-chain gene (IgV(H)) status; 8 of 25 patients (32%) had 11q-, with four of them also displaying unmutated IgV(H); and six (24%) had 17p- (five were also unmutated). RESULTS: After a median follow-up of 47.3 months, all 22 patients alive are disease free; overall survival and event-free survival (EFS) at 6 years were 70% and 72%, respectively. According to molecular/cytogenetic characteristics, overall survival and EFS for unmutated CLL and/or with 11q- aberration (n = 13) were 90% and 92%, respectively, not significantly different to those with normal in situ hybridization, 13q- and +12, or mutated CLL (n = 7). All six patients with 17p deletion were transplanted with active disease, including three with refractory disease; all except one reached complete remission after the transplant and two are alive and disease free. Nonrelapse mortality (NRM) was 20%; more than two lines before transplant is an independent prognostic factor for NRM (P = 0,02), EFS (P = 0.02), and overall survival (P = 0.01). Patients older than 55 years have a higher risk of NRM (hazard ratio, 12.8; 95% confidence interval, 1.5-111). Minimal residual disease was monitored by multiparametric flow cytometry in 21 patients. Clearance of CD79/CD5/CD19/CD23 cells in bone marrow was achieved in 68% and 94% of the patients at days 100 and 360, respectively. CONCLUSION: According to these results, RIC allogeneic transplant could overcome the adverse prognosis of patients with unmutated CLL as well as those with 11q- or 17p-. 相似文献
127.
128.
Antonio B de Luna Javier García-Niebla Adrian Baranchuk 《Current Cardiology Reviews》2014,10(3):175-180
Brugada syndrome is a genetically determined familial disease with autosomal dominant transmission and variable penetrance, conferring a predisposition to sudden cardiac death due to ventricular arrhythmias. The syndrome is characterized by a typical electrocardiographic pattern in the right precordial leads. This article will focus on the new electrocardiographic features recently agreed on by expert consensus helping to identify this infequent electrocardiographic pattern. 相似文献
129.
130.